NCT02506335View on ClinicalTrials.gov

Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

May 1, 2018

Study Completion Date

May 1, 2018

Conditions
Liver DiseaseCardiovascular Disease
Interventions
DRUG

Cholate testing

The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

lead

Northwestern University

OTHER

NCT02506335 - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease | Biotech Hunter | Biotech Hunter